Health News Highlights: Drug Development, E. coli Outbreaks, CTE Concerns, and PFAS Settlements

Recent health updates include Vertex halting painkiller development due to trial setbacks; Florida reports E.coli cases linked to raw milk; a Manhattan shooting heightens concussion awareness in sports; and Chemours, DuPont, and Corteva settle PFAS lawsuits for $875 million.

Vertex Pharmaceuticals has decided to cease the development of its experimental painkiller VX-993 after the drug failed to achieve significant results in a mid-stage trial. This decision prompted a significant drop in their stock price.

In Florida, health officials have identified 21 E. coli and Campylobacter cases linked to raw milk consumption from a specific farm, resulting in seven hospitalizations and raising public health concerns.

A tragic shooting in Manhattan has brought renewed focus on the management of head injuries in amateur sports. Former football player Shane Tamura's actions, connected to CTE, have sparked debate over concussion protocols.

In environmental news, a historic $875 million settlement has been reached with Chemours, DuPont, and Corteva over PFAS chemical pollution claims in New Jersey, reflecting growing legal and regulatory action against such contamination.

(With inputs from agencies.)